Yaldigo 1600 mg, magensaftresistente Tablette - 90 Swissmedic Key 53108003 Registration Holder Tillotts Pharma AG Name Yaldigo 1600 mg, magensaftresistente Tablette Date of registration 15.11.1994 Introduction of Sequence 17.07.2019 ATC-Classification Mesalazine (A07EC02) Revision date 12.03.2004 WHO WHO-DDD Valid until Index Therapeuticus (BSV) 04.09. Show package size 90 Index Therapeuticus (Swissmedic) 04.09. Description Swissmedic categorie. B SL Eintrag No Indication Information for professionals IP Consumer information Ex-factory-Price PR Deductible k.A. Consumer price PR Feedback FB GTIN 7680531080035 Medication Code Synthetika Pharmacode Disponibility
Composition mesalazinum 1600 mg, cellulosum microcristallinum, carboxymethylamylum natricum A corresp. natrium 2.268 mg, hypromellosum, silica colloidalis, magnesii stearas, Überzug: hypromellosum, macrogolum 6000, acidi methacrylici et methylis methacrylatis polymerisatum 1:2, triethylis citras, glyceroli monostearas 40-55, polysorbatum 80, kalii dihydrogenophosphas, maydis amylum, E 172, pro compresso obducto. Packungsbestandteile Galenic Form Gastric juice resistant tablets Active Agent Dose Mesalazine 1600 mg
BAG: Active Agent Dose Mesalazine 1600 mg
Inactive agents Dose additional_information Acidi Methacrylici Carboxymethylamylum Natricum A Cellulosum Microcristallinum E 172 color. Glyceroli Monostearas 40-55 Hypromellosum Überzug Potassium Dihydrogenophosphate Macrogol 6000 Magnesii Stearas Maydis Amylum Methylis Methacrylatis Polymerisatum Polysorbatum 80 Pro Compresso Obducto Silica Colloidalis Triethylis Citras
Source Data was imported : 06.12.2023
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
